Participating Companies

Alladapt Immunotherapeutics, Inc.
Al­la­dapt is rei­magin­ing the treat­ment of food al­ler­gy, de­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is cur­rent­ly in a Phase 1/2 clin­i­cal trial, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. [more in­for­ma­tion]
Amphista Therapeutics
Iden­ti­fied nov­el de­grad­ing mech­anisms in­de­pen­dent of typ­i­cal E3 li­g­as­es • Build­ing on strengths of TPD while di­rect­ly ad­dress­ing lim­i­ta­tions • De­mon­s­trat­ed su­pe­ri­or­i­ty over other TPD ap­proach­es across three se­parate ar­eas: in­creased scope, im­proved drug­like prop­er­ties and re­duced re­sis­tance po­ten­tial • Ini­tial fo­cus in On­col­o­gy with scope to ex­pand in­to fur­ther ther­a­py ar­eas, in­clud­ing CNS dis­eas­es Am­phis­ta Ther­a­peu­tics suc­cess­ful­ly closed an over­sub­scribed $53M Se­ries B round in March 2021, build­ing on an ini­tial $7.5M Se­ries A fund­ing raised in April 2020. [more in­for­ma­tion]
Arbor Biotechnologies
An ear­ly-stage life sci­ences com­pany pi­oneer­ing the next-gen­er­a­tion of ge­net­ic medicines. With the most ex­ten­sive li­brary of CRIS­PR nu­cleas­es in the in­dus­try, a deep bench of world-class foun­ders (in­clud­ing gene edit­ing pi­oneer Feng Zhang) and sci­en­tif­ic ad­vi­sors, and a lead­er­ship team with a proven track re­cord of de­vel­op­ing nov­el plat­forms and ther­a­peu­tics, Ar­bor is well-po­si­tioned to de­vel­op cu­ra­tive ge­net­ic medicines for all pa­tients with ge­net­ic dis­eas­es. [more in­for­ma­tion]
Op­er­a­tor of an ar­ti­fi­cial in­tel­li­gence-based biotech­nol­o­gy com­pany in­tend­ed to help in­vent new po­ten­tial medicines for more than 50 dis­ease tar­gets. The com­pany's tech­nol­o­gy helps in drug hit dis­cov­ery, bind­ing affini­ty pre­dic­tion and toxic­i­ty de­tec­tion, en­abling sci­en­tists to dis­cov­er small molecules for the treat­ment and in­vesti­ga­tion of hu­man dis­eas­es. [more in­for­ma­tion]
De­vel­op­er of a plat­form to dis­cov­er ef­fec­tive treat­ment ap­proach­es for ev­ery dis­ease. The com­pany's gene cir­cuit­ry plat­form solves the cir­cuit­ry code, unique to each hu­man gene, fa­cil­i­tat­ing the rapid dis­cov­ery of new treat­ments. Its 4D maps iden­ti­fy de-risked drug­gable tar­gets, pro­duce ac­tion­able in­sights and im­prove ther­a­peu­tic pre­dicta­bil­i­ty. [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Catamaran Bio
The Com­pany is us­ing its TAIL­WINDTM Plat­form, an in­te­grat­ed suite of tech­nolo­gies, to spe­cif­i­cal­ly ad­dress the end-to-end meth­ods of en­gi­neer­ing, pro­cess­ing and man­u­fac­tur­ing NK cells and rapid­ly ad­vance its pipe­line of CAR-NK cell ther­a­py pro­grams. [more in­for­ma­tion]
Celsius (Biotechnology)
Provider of a plat­form in­tend­ed to re­search on sin­gle-cell RNA se­quenc­ing and ge­nom­ic anal­y­sis to de­vel­op life-chang­ing medicines. The com­pany's plat­form ap­plies sys­te­m­at­ic ap­proach to sin­gle-cell se­quenc­ing, com­bin­ing mas­sive da­tasets and al­go­rithms in or­der to dis­cov­er pre­ci­sion ther­a­pies, en­abling doc­tors to im­pact on the lives of pa­tients with au­toim­mune dis­eas­es and can­cer. [more in­for­ma­tion]
Chameleon Biosciences
The com­pany's tech­nolo­gies in­clude ef­fec­tor vec­tors and exo-AAV which are not con­s­trained by the same im­mune sys­tem lim­i­ta­tions that pre­vent more wide­spread use of cur­rent AAV gene ther­a­pies, en­abling pa­tients to treat rare dis­eas­es with ge­net­ic medicines ad­min­is­tered as many times as need­ed. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
En­terome is lev­er­ag­ing this ex­per­tise to de­vel­op a pipe­line of clin­i­cal and pre-clin­i­cal can­di­dates (small molecules, pro­teins and pep­tides) with a fo­cus on can­cer, au­toim­mune, in­flam­ma­to­ry and metabolic dis­eas­es. [more in­for­ma­tion]
Evox Therapeutics
Ex­o­some-based drugs have the po­ten­tial to ad­dress some of the lim­i­ta­tions of pro­tein, anti­body and nu­cle­ic acid-based ther­a­pies by en­abling de­liv­ery to cells and tis­sues that are cur­rent­ly out of reach us­ing other drug de­liv­ery tech­nolo­gies, and Evox is lead­ing the de­vel­op­ment within this emerg­ing ther­a­peu­tic space. [more in­for­ma­tion]
Hangzhou Chance Pharmaceuticals
Chance fo­cus­es on in­ha­la­tion prod­ucts with pro­pri­e­tary tech­nolo­gies. [more in­for­ma­tion]
HotSpot Therapeutics
The com­pany helps to iden­ti­fy hotspots and lo­cate path­way treat­ments for can­cer, metabolic and rare dis­eas­es. Its plat­form lev­er­ages a database of hotspot struc­tures, har­ness­ing the pow­er of da­ta sci­ence in its mul­tidis­ci­pli­nary ap­proach to drug dis­cov­ery. [more in­for­ma­tion]
Impact Therapeutics Inc
Im­pact Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cates to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. [more in­for­ma­tion]
Im­vax™ is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cused on the de­vel­op­ment of nov­el pa­tient-spe­cif­ic vaccines and im­munother­a­py strate­gies for the treat­ment of ma­lig­nant glio­mas and other can­cers with un­met med­i­cal needs. [more in­for­ma­tion]
In­vetx is build­ing the world’s pre­mi­er biotech­nol­o­gy plat­form for pro­tein-based ther­a­peu­tics in an­i­mal health to trans­form stan­dards of care in ve­t­eri­nary medicine. The In­vetx team of high­ly ex­pe­ri­enced R&D lead­ers from both hu­man biotech and an­i­mal health is sup­port­ed by best-in-class biotech­nol­o­gy part­n­ers and an ex­ten­sive net­work of in­dus­try ex­perts, ve­t­eri­nary sci­en­tists and clini­cians. In­vetx is a pri­vate com­pany head­quar­tered in Bos­ton, Mas­sachusetts. [more in­for­ma­tion]
Lassen Therapeutics
IL-11, a mem­ber of the IL-6 fam­i­ly of cy­tokines, is a cen­tral me­di­a­tor of fi­bro­sis and block­ing its ac­tiv­i­ty has the po­ten­tial to be more ef­fec­tive than tar­get­ing other fac­tors such as TGF-&be­ta; and CT­GF. IL-11 is al­so a piv­o­tal ef­fec­tor of tu­mor mi­croen­vi­ron­ment or­gani­za­tion and tu­mor growth, play­ing a key role as a me­di­a­tor be­tween can­cer and stro­mal cells. [more in­for­ma­tion]
LiPac Oncology
LI­PAC On­col­o­gy is a phar­ma­ceu­ti­cal com­pany fo­cused on ad­vanc­ing the de­vel­op­ment of new in­vesti­ga­tio­n­al ther­a­pies to treat in­tra­cav­i­tary can­cers. Li­Pax, its lead in­vesti­ga­tio­n­al can­di­date for the treat­ment of non-mus­cle in­va­sive blad­der can­cer, is in Phase 2b de­vel­op­ment. [more in­for­ma­tion]
MiNA Therapeutics
Ver­satile, pro­pri­e­tary small ac­ti­vat­ing ri­bonu­cle­ic acid (saR­NA) ther­a­peu­tics plat­form and in­ter­nal pipe­line, ini­tial­ly fo­cus­ing on on­col­o­gy and rare dis­ease in­di­ca­tions. Pre­par­ing to ini­ti­ate ran­domized Ph2 study for lead saR­NA drug can­di­date MTL-CEB­PA com­bined with so­rafenib in se­cond line he­p­a­to­cel­lu­lar car­ci­no­ma. [more in­for­ma­tion]
Minerva Biotechnologies
im­munother­a­pies for can­cer and cel­lu­lar ther­a­pies in re­gen­er­a­tive medicine. First-in-hu­man trial of huM­NC2-CAR44, a CAR T ther­a­py tar­get­ing MUC1* in me­tastat­ic breast can­cers in pa­tients with MUC1* re­ac­tive tu­mors. IND for 1XX ver­sion of this CAR T, which great­ly in­creas­es per­sis­tence and recog­ni­tion of low anti­gen den­si­ty cells will be filed in 2021. [more in­for­ma­tion]
MISSION Therapeutics
Mis­sion Ther­a­peu­tics is an ear­ly-stage drug de­vel­op­ment com­pany tar­get­ing the ubiquitin path­way for the treat­ment of neu­rode­gen­er­a­tive dis­ease, rare mi­to­chon­drial dis­eas­es and fi­bro­sis. [more in­for­ma­tion]
NKGen Biotech
is a clin­i­cal-stage biotech­nol­o­gy com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of unique au­tol­o­gous, al­lo­gene­ic, and CAR-NK Na­t­u­ral Killer (NK) Cell ther­a­pies. [more in­for­ma­tion]
NodThera Limited
Op­er­a­tor of a clin­i­cal-stage biotech­nol­o­gy com­pany in­tend­ed to de­vel­op medicines to treat dis­eas­es driv­en by chron­ic in­flam­ma­tion. The com­pany is fo­cused on de­vel­op­ing a new class of po­tent and se­lec­tive NL­R­P3 in­flam­ma­some in­hibi­tors, pro­vid­ing med­i­cal prac­ti­tion­ers with tools to help pa­tients with many chron­ic dis­eas­es. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
The com­pany's tech­nol­o­gy lev­er­ages the hu­man im­mune sys­tem to iden­ti­fy ful­ly hu­man mon­o­clo­n­al anti­bodies and dis­cov­er nov­el tar­gets that will lead to the de­vel­op­ment of anti­body-de­rived ther­a­peu­tics for the treat­ment of can­cer, pro­vid­ing a larg­er num­ber of can­cer pa­tients with the ben­e­fit of im­munother­a­py. [more in­for­ma­tion]
Strong R&D team with in­dus­try vet­er­ans in mAb/ADC dis­cov­ery and physics based mod­el­ing pro­vides Orum with an un­matched R&D en­gine to dis­cov­er and de­vel­op mul­ti­ple plat­forms with pipe­line prod­ucts with pre­ci­sion and speed. [more in­for­ma­tion]
Plex­i­um’s tar­get­ed pro­tein degra­da­tion plat­form, DELPhe®, en­ables the dis­cov­ery of nov­el small molecules with cell-based ac­tiv­i­ty that redi­rect E3 li­g­as­es to patho­genic pro­teins of in­ter­est or in­duce degra­da­tion of patho­genic pro­teins by di­rect­ly bind­ing to them. [more in­for­ma­tion]
He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. Prile­nia is fo­cused on de­vel­op­ing nov­el treat­ments for neu­rode­gen­er­a­tive and neu­rode­vel­op­men­tal di­s­or­ders. [more in­for­ma­tion]
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Revitope Oncology
The lead­ing next gen­er­a­tion con­di­tio­n­al­ly ac­ti­vat­ed T cell en­gager com­pany lev­er­ag­ing its Two­GATE™ plat­form to ad­dress ar­eas of un­met need for safer and more ef­fec­tive can­cer im­munother­a­pies. Re­vi­tope’sT­wo­GATE™ drugs tar­get a pair of anti­gens co-ex­pressed on the sur­face of can­cer cells to achieve an un­par­al­leled de­gree of tu­mor se­lec­tiv­i­ty and avoid toxic­i­ty on healthy cells and tis­sues.” [more in­for­ma­tion]
San­i­fit is a bio­phar­ma­ceu­ti­cal com­pany fo­cused on treat­ments for cal­ci­fi­ca­tion di­s­or­ders, with SN­F472 as the lead com­pound. The com­pany is plan­n­ing to ini­ti­ate a phase III study in this or­phan dis­ease in 2018. The on­go­ing phase IIb study (Calip­so) in ES­RD pa­tients on dial­y­sis is eval­u­at­ing the ef­fect of SN­F472 on pro­gres­sion of ar­te­rial cal­ci­fi­ca­tion. [more in­for­ma­tion]
The Com­pany is sup­port­ed by a strong, in­ter­na­tio­n­al­ly renowned team who aim to har­ness the po­ten­tial of ge­nom­ic medicine to de­liv­er new treat­ments to all oc­u­lar dis­ease pa­tients as quick­ly as pos­si­ble. [more in­for­ma­tion]
Systems Oncology
Dde­vel­op­ing a new class of mul­ti­mo­dal RNA ther­a­peu­tics that si­mul­ta­ne­ous­ly si­lence the right com­bi­na­tion of dis­ease tar­gets with a sin­gle RNA molecule to im­prove out­comes and com­bat emerg­ing drug re­sis­tance. Our Ar­romerTM plat­form is used to dig­i­tal­ly en­gi­neer and rapid­ly pro­duce self-de­liv­er­ing ther­a­peu­tics which are di­rect­ed to spe­cif­ic tis­sues with un­prece­dent­ed pre­ci­sion and ac­cu­ra­cy. We are fo­cused on build­ing a pipe­line of drug prod­ucts in on­col­o­gy, yet our mul­ti­mo­dal RNA ther­a­peu­tics plat­form can be [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. [more in­for­ma­tion]
Totus Medicines
[more in­for­ma­tion]
Treos Bio Limited
Pipe­line in­cludes per­so­n­al­ized + off-the-shelf ther­a­pies for mul­ti­ple solid can­cers and an IND-ready 2nd gen­er­a­tion COVID T-cell vaccine. Their lead pro­grams in­clude treat­ment for MSS col­orec­tal can­cer, with strong Ph1/2 re­sults, and clin­i­cal col­lab­o­ra­tions with Roche and Mayo Clin­ic. [more in­for­ma­tion]
XyloCor Therapeutics
Xy­lo­Cor Ther­a­peu­tics is a bio-phar­ma­ceu­ti­cal com­pany in­tend­ed to de­vel­op gene ther­a­py for peo­ple with ad­vanced coro­nary artery dis­ease. [more in­for­ma­tion]